PMID- 35015825
OWN - NLM
STAT- MEDLINE
DCOM- 20220509
LR  - 20220608
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 6
IP  - 9
DP  - 2022 May 10
TI  - Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD 
      after CAR T-cell therapy.
PG  - 2867-2871
LID - 10.1182/bloodadvances.2021006715 [doi]
AB  - About 70% of patients with large B-cell lymphoma (LBCL) who are treated with 
      axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or 
      stable disease (SD) on the day 30 (D30) positron emission tomography 
      (PET)-computed tomography (CT) scan progress; however, the factors that are 
      predictive of progression are unknown. This a retrospective study of patients 
      with LBCL who were treated with axi-cel at MD Anderson Cancer Center between 
      January of 2018 and February of 2021. Among 50 patients with D30 PR/SD, 13 (26%) 
      converted to a complete response (CR). Among 95 patients with a D30 CR, 72 (76%) 
      remained in CR. On univariate analysis, the only day -5 characteristic associated 
      with conversion from D30 PR/SD to subsequent CR was a higher platelet count (P = 
      .05). The only D30 factor associated with conversion from D30 PR/SD to subsequent 
      CR was a lower maximum standardized uptake volume (SUVmax; P < .001); all 
      patients with D30 SUVmax >/= 10 progressed. After a median follow-up of 12 months, 
      no significant difference in median progression-free survival was observed 
      between patients who converted from D30 PR/SD to subsequent CR and those who had 
      been in CR since D30 (P = .19). Novel predictive and prognostic markers based on 
      tissue biopsy and noninvasive diagnostic assays are needed to more effectively 
      identify these patients and characterize the biology of their residual disease.
CI  - (c) 2022 by The American Society of Hematology. Licensed under Creative Commons 
      Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), 
      permitting only noncommercial, nonderivative use with attribution. All other 
      rights reserved.
FAU - Al Zaki, Ajlan
AU  - Al Zaki A
AD  - Department of Lymphoma and Myeloma.
FAU - Feng, Lei
AU  - Feng L
AD  - Department of Biostatistics, and.
FAU - Watson, Grace
AU  - Watson G
AD  - Department of Lymphoma and Myeloma.
FAU - Ahmed, Sairah A
AU  - Ahmed SA
AUID- ORCID: 0000-0001-7302-8299
AD  - Department of Lymphoma and Myeloma.
FAU - Mistry, Haleigh
AU  - Mistry H
AD  - Department of Lymphoma and Myeloma.
FAU - Nastoupil, Loretta J
AU  - Nastoupil LJ
AD  - Department of Lymphoma and Myeloma.
FAU - Hawkins, Misha
AU  - Hawkins M
AD  - Department of Lymphoma and Myeloma.
FAU - Nair, Ranjit
AU  - Nair R
AD  - Department of Lymphoma and Myeloma.
FAU - Iyer, Swaminathan P
AU  - Iyer SP
AD  - Department of Lymphoma and Myeloma.
FAU - Lee, Hun J
AU  - Lee HJ
AD  - Department of Lymphoma and Myeloma.
FAU - Steiner, Raphael E
AU  - Steiner RE
AUID- ORCID: 0000-0003-3717-3629
AD  - Department of Lymphoma and Myeloma.
FAU - Flowers, Christopher R
AU  - Flowers CR
AD  - Department of Lymphoma and Myeloma.
FAU - Shpall, Elizabeth J
AU  - Shpall EJ
AD  - Department of Stem Cell Transplantation, The University of Texas MD Anderson 
      Cancer Center, Houston, TX.
FAU - Kebriaei, Partow
AU  - Kebriaei P
AD  - Department of Stem Cell Transplantation, The University of Texas MD Anderson 
      Cancer Center, Houston, TX.
FAU - Neelapu, Sattva S
AU  - Neelapu SS
AUID- ORCID: 0000-0003-1045-4914
AD  - Department of Lymphoma and Myeloma.
FAU - Westin, Jason R
AU  - Westin JR
AUID- ORCID: 0000-0002-1824-2337
AD  - Department of Lymphoma and Myeloma.
FAU - Strati, Paolo
AU  - Strati P
AD  - Department of Lymphoma and Myeloma.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Antigens, CD19
MH  - Humans
MH  - *Immunotherapy, Adoptive/methods
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - Progression-Free Survival
MH  - Retrospective Studies
PMC - PMC9092420
EDAT- 2022/01/12 06:00
MHDA- 2022/05/10 06:00
PMCR- 2022/05/05
CRDT- 2022/01/11 17:39
PHST- 2021/11/29 00:00 [received]
PHST- 2021/12/23 00:00 [accepted]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/05/10 06:00 [medline]
PHST- 2022/01/11 17:39 [entrez]
PHST- 2022/05/05 00:00 [pmc-release]
AID - 483436 [pii]
AID - 2022/ADV2021006715 [pii]
AID - 10.1182/bloodadvances.2021006715 [doi]
PST - ppublish
SO  - Blood Adv. 2022 May 10;6(9):2867-2871. doi: 10.1182/bloodadvances.2021006715.